Form 4: Immix Biopharma CFO Gabriel Morris Buys $5,298 Worth of Shares

Gabriel Morris, CFO of Immix Biopharma, recently purchased 2,500 shares of the company's common stock at a price of $2.1192 per share.

Summary

• On June 7, 2024, Gabriel Morris, the CFO of Immix Biopharma, Inc., acquired 2,500 shares of common stock at a price of $2.1192 per share.
• The total value of the purchase was $5,298.
• Following the transaction, Morris directly owns 285,834 shares of Immix Biopharma's common stock.
• Morris also indirectly owns 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures I, LP.
• Morris disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CFO's purchase is a positive signal, but the amount is relatively small. The filing itself is a routine regulatory requirement.

Positives

• The CFO's purchase of shares could be interpreted as a positive signal about his confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Monitoring insider trading activity is a common practice in the financial industry.
• Investors often compare insider trading patterns to those of peer companies to assess relative valuation and management confidence.
• A purchase by a CFO is generally viewed more positively than a sale, but the significance depends on the size of the transaction relative to their existing holdings and the company's market capitalization.

Key Dates